Pharma Investments, Ventures & Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures & Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Adverse Drug Reactions
Napo Announces Successful Clinical Results in Phase 2 Study of Crofelemer in Acute Adult Infectious Diarrhea
May 4th, 2008
Napo Pharmaceuticals, Inc., is pleased to announce the positive results of a successfully completed Phase 2 trial for CRO-ID (crofelemer for the treatment of acute adult infectious diarrhea) conducted by its partner, Glenmark Pharmaceuticals Limited . The primary endpoints of the trial were stool weight, duration of diarrhea, stool frequency and stool consistency; additional endpoints followed include degree of patient dehydration and reduction in gastrointestinal index score. The conclusions from the study were that treatment with crofelemer was well tolerated and resulted in statistically significant improvements in all the primary endpoints and statistically...
Source: Pharma Investments, Ventures & Law Weekly (2008-05-04)
|
